Ketamine and psilocybin each produce a brief acute experience but set off a wave of synaptic growth afterward, ketamine through glutamate release and mTOR-dependent synapse formation and psilocybin through rapid, lasting growth of dendritic spines in the frontal cortex, both via BDNF signaling, which is why a single session can shift symptoms for weeks
FDA approval requires formal clinical trials, safety and efficacy review, labeling approval, and manufacturing validation under a New Drug Application (NDA) or Biologics License Application (BLA)
No EMA (European Medicines Agency) or MHRA approval exists for any indication
MK-677 causes marked appetite increase in 6080% of users, weight gain of 25 kg in the first month, elevated fasting glucose, and lethargy 24 hours post-dose
The peptide stays stable for full twenty-eight days refrigerated
With the consistent application of the peptide alone, this skin-healing evidence (Seiwerth et al., 1997